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Abstract
The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first-line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher-risk populations with relapsed/refractory
(R/R) disease. The objective of this study was to evaluate outcomes of ibrutinib-treated
patients based on prior lines of therapy, including after ibrutinib discontinuation. Data
were analyzed from two multicenter phase 3 studies of single-agent ibrutinib: RESONATE (PCYC-1112) in patients with R/R CLL and RESONATE-2 (PCYC-1115) in patients
with treatment-naive (TN) CLL without del(17p). This integrated analysis included
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medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
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271 ibrutinib-treated non-del(17p) patients with CLL (136 TN and 135 R/R). Median
progression-free survival (PFS) was not reached for subgroups with 0 and 1/2 prior therapies but was 40.6 months for patients with ≥3 therapies (median follow-up: TN,
36 months; R/R, 44 months). Median overall survival (OS) was not reached in any subgroup. Overall response rate (ORR) was 92% in TN and 92% in R/R, with depth of
response increasing over time. Adverse events (AEs) and ibrutinib discontinuation due to
AEs were similar between patient groups. Most patients (64%) remain on treatment. OS
following discontinuation was 9.3 months in R/R patients (median follow-up 18 months,
n = 51) and was not reached in TN patients (median follow-up 10 months, n = 30). In this
integrated analysis, ibrutinib was associated with favorable PFS and OS, and high ORR
regardless of prior therapies in patients with CLL. The best outcomes following ibrutinib
discontinuation were for patients receiving ibrutinib in earlier lines of therapy.

in TN patients ≥65 years of age6 and RESONATE (NCT01578707)

1 | I N T RO D UC T I O N

in patients with CLL treated with ≥1 prior therapy, as previously
The B-cell receptor (BCR) signaling pathway has emerged as an

described.6,7 RESONATE-2 excluded patients with del(17p); there-

important therapeutic target for B-cell malignancies, including chronic

fore, this subgroup was also excluded from RESONATE for this

lymphocytic leukemia (CLL).1 Bruton's tyrosine kinase (BTK), a com-

analysis to ensure a homogeneous dataset. Patients treated with

ponent of signaling via the BCR, plays a role in the survival, prolifera-

1 to 2 prior lines of therapy were combined because the number of

tion, tissue adhesion, and migration of CLL cells.

1–5

Ibrutinib, a first-

patients treated with one prior therapy was small (n = 27).

in-class, once-daily oral BTK inhibitor, is indicated by the United

In both studies, patients on the ibrutinib arm received ibruti-

States Food and Drug Administration and the European Medicines

nib 420 mg once daily continuously. Patients on the comparator

Agency for treating patients with CLL, including del(17p) CLL, and

arm received up to 12 cycles of chlorambucil (RESONATE-2)

allows for treatment without chemotherapy. Results from the phase

or 24 weeks of intravenous ofatumumab (RESONATE), and

3 RESONATE-2 study (PCYC-1115) of ibrutinib versus chlorambucil

those patients with progression confirmed by an Independent

in treatment-naive (TN) patients with CLL showed significantly pro-

Review Committee were allowed to cross over to ibrutinib.6,7

longed progression-free survival (PFS) and overall survival (OS) with

Details regarding drug administration have been previously

ibrutinib.6 In patients with relapsed/refractory (R/R) CLL, the phase

published. 6,7

3 RESONATE study (PCYC-1112) of ibrutinib versus ofatumumab

Clinical end points included PFS, OS, overall response rate (ORR),

showed superior PFS and OS with ibrutinib.7 Data from RESONATE

and safety (grading of severity of adverse events [AEs] based on

suggest that outcomes with ibrutinib in the relapsed setting vary by

CTCAE 4.0). In addition, OS post-discontinuation of ibrutinib and

extent of prior therapy; patients treated with ibrutinib after one prior reg-

comparator treatments were assessed. PFS and ORR were based on

imen experience significantly longer PFS than patients treated in later

investigator assessment.

lines.8 As BCR signaling inhibitors are only recently available for CLL, and

Studies were approved by the institutional review boards at each

patients discontinue infrequently, few studies have evaluated patient

participating institution and conducted in accordance with the Decla-

outcomes following cessation of ibrutinib. Recent institutional analyses

ration of Helsinki. All patients provided written informed consent.

that included high-risk, multiply relapsed patients reported poor survival

RESONATE and RESONATE-2 were registered at www.clinicaltrials.

in those who discontinued ibrutinib.9,10 We conducted an integrated

gov as NCT01578707 and NCT01722487.

analysis of two phase 3 studies to evaluate outcomes with ibrutinib in
CLL based on the number of prior lines of therapy, including after ibrutinib discontinuation.

2 | PATI ENT S AND M ET HODS
2.1 | Patients, treatment regimen, and clinical end
points

2.2 | Statistical considerations
Patient subgroups were defined according to the number of lines of
therapy received before ibrutinib (0, 1-2, ≥3 prior lines). Descriptive
analysis was used to summarize demographics, baseline characteristics, and safety. OS post-discontinuation was measured from the date
of ibrutinib discontinuation to the date of last follow-up or death.

Data were analyzed from patients from two multicenter, randomized

Time-to-event end points were estimated using the Kaplan-Meier

phase 3 studies of single-agent ibrutinib: RESONATE-2 (NCT01722487)

method.
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3 | RESULTS

3.2 | Efficacy
Median follow-up was 36 months for TN patients and 44 months for

3.1 | Patients

R/R patients (44 mo with 1-2 prior; 44 mo with ≥3 prior). Median PFS

This integrated analysis included 271 ibrutinib-treated patients: 136 from

was not reached for patients with 0 and 1-2 prior therapies, and was

RESONATE-2 and 135 from RESONATE (1-2 prior, 68; ≥3 prior, 67).

40.6 months in patients with ≥3 prior therapies (Figure 1). The differ-

TN patients were older and had a lower frequency of high-risk genomic

ences in PFS between 0 versus ≥3 lines of therapy and 1-2 versus ≥3

abnormalities, such as del(11q) and complex karyotype relative to the

lines of therapy were significant (P < 0.0001 and P = 0.0109, respec-

R/R group (Supporting Information Table 1).

tively); the difference in PFS between 0 versus 1-2 lines of therapy
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F I G U R E 1 Progression-free
survival and overall survival with
ibrutinib by prior lines of therapy.
A, Progression-free survival by
investigator assessment. B, Overall
survival. Median follow-up times by
subgroups were 36 months for
0 prior and 44 months for 1/2 prior
and ≥3 prior. The tick marks indicate
patients with censored data. NE, not
estimable; NR, not reached; OS,
overall survival; PFS, progressionfree survival
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was not significant (P = 0.2387). The 36-month PFS rate for each

The ORR was 92% (complete response [CR], 22%) in TN patients

group was 81%, 74%, and 54%, respectively. In patients with del(11q),

and 92% (CR, 7%) across previously treated subgroups (96% [CR, 6%]

median PFS was 38.5 months for patients with ≥3 prior therapies, and

for 1-2 prior treatments and 88% [CR, 7%] for ≥3 prior therapies).

was not reached for patients with 0 to 2 prior therapies (data not

Analysis of cumulative response over time showed that response

shown). Median OS was not reached in any subgroup. The difference

rates (including CRs) increased regardless of lines of therapy

in OS between 0 versus ≥3 lines of therapy was significant

(Figure 2), particularly in those who received ibrutinib as their initial

(P = 0.0091); differences in OS between 0 versus 1-2 lines of therapy

treatment. The median time to CR was 20 months (range, 7-38) for

and 1-2 versus ≥3 lines of therapy were not significant (P = 0.2349 and

TN patients, 10 months (range, 6-14) for patients with 1-2 prior lines,

P = 0.2375, respectively). The 36-month OS rate was 88%, 83%, and

and 17.5 months (range, 5-36) for patients with ≥3 prior lines of

75% for patients with 0, 1-2, or ≥3 prior therapies, respectively.

therapy.
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complete response; PR, partial response;
PRL, PR with lymphocytosis; nPR,
nodular PR
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Most patients with baseline anemia (hemoglobin ≤11 g/dL) or

disorders (3%/2%); and blood and lymphatic system disorders

baseline thrombocytopenia (platelet count ≤100 × 109/L) experi-

(1%/2%). The most common AEs leading to dose reductions (in >2

enced sustained improvement, regardless of previous lines of therapy

patients) included neutropenia (n = 5; 2%), atrial fibrillation (n = 4;

(Supporting Information Table 2).

1%), and anemia, thrombocytopenia, diarrhea, and arthralgia (n = 3;
1% each). Overall, discontinuation due to PD occurred in 32 of

3.3 | Concomitant hematologic support measures

271 patients (12%), including five TN patients (4%; one patient had
Richter's transformation) and 27 R/R patients (20%; six patients had

Patients received hematologic support, including growth factors,

Richter's transformation), and occurred less frequently in patients

transfusions, and intravenous immunoglobulin (IVIG) (Supporting

treated with ibrutinib in earlier lines of therapy (Supporting Informa-

Information Table 3). Rates of neutrophil growth factor use were

tion Table 6).

10% in the TN subgroup, 28% in patients with 1-2 prior therapies,
and 24% in the ≥3 prior therapies subgroup. Rates of IVIG use were
5% in patients with 0 prior therapies, 24% in the 1-2 prior therapies

3.6 | Outcomes following ibrutinib discontinuation

subgroup, and 51% in the ≥3 prior therapies subgroup. Red blood

Data from 30 TN and 52 R/R patients were evaluated for outcomes

cell and platelet transfusions were also more frequent among

following ibrutinib discontinuation (Table 1). The median OS following

patients treated with ibrutinib in later lines (Supporting Information

discontinuation was not reached for TN patients (n = 30), 9.3 months

Table 3).

for patients with 1-2 prior therapies (n = 22), and 8.9 months for
patients with ≥3 prior therapies (n = 30) at median follow-ups of

3.4 | Safety

10, 15, and 18 months, respectively.
For comparison, 117 patients on the comparator arms were eval-

The rate of common AEs by number of prior lines of therapy is shown

uated for outcomes following discontinuation of chlorambucil for TN

in the Supplement for all grade AEs and for ≥3 AEs (Supporting Infor-

patients and ofatumumab for the R/R subgroup. Median OS follow-

mation Tables 4 and 5). The frequency of AEs generally decreased

ing discontinuation was 30.7 months for TN patients, 8 months for

with time, with AEs in the second and subsequent years of ibrutinib

patients treated with ≥3 prior therapies, and was not reached in

therapy occurring less frequently relative to the first year (Figure 3).

patients with 1-2 prior therapies (Supporting Information Table 7).

Hypertension of any grade occurred more frequently after the first

When 52 patients who received ibrutinib after crossover were

year (8% during first year, 15% in year 2, 20% in year 3, and 19% in

excluded, median OS was 29.4 months for TN patients, versus 2.5 to

years >3) in previously treated patients; more frequent grade ≥3

2.7 months for patients with ≥1 prior therapy (Supporting Informa-

hypertension events also occurred after the first year (Figure 3B).

tion Table 7).

Fatal AEs occurred in 11 (8%) TN patients and 11 (8%) R/R patients

Data on subsequent therapy following ibrutinib discontinuation

over the 37 months of follow-up. Fatal AEs included subdural hema-

were available for nine TN patients and 31 R/R patients (Supporting

toma (n = 1), infections or infectious complications (n = 7), other neo-

Information Table 8), with several of these patients receiving multiple

plasms including Richter's transformation (n = 4), myocardial infarction

subsequent therapies. Data on best responses to the first subsequent

(n = 2), small intestinal obstruction (n = 1), pulmonary fibrosis (n = 1),

therapy after ibrutinib were available for seven TN patients (six PRs

and other/not specified (n = 6).

following chemotherapy, or chemoimmunotherapy and one SD following radiation therapy).

3.5 | Treatment exposure and discontinuation

Patients given ibrutinib as second-line or third-line therapy,
subsequently received chemoimmunotherapy regimens including

Median duration of ibrutinib treatment was 36 months (range,

rituximab with cyclophosphamide, doxorubicin, vincristine, and

1-43), 43 months (range, 1-50), and 39 months (range, 1-50) in

prednisone (R-CHOP), modified R-CHOP, and rituximab, etoposide,

patients with 0, 1-2, and ≥3 prior treatments, respectively, and the

prednisone, vincristine, cyclophosphamide, and doxorubicin (R-

majority of patients continued on ibrutinib (Supporting Information

EPOCH), as well as a range of newer therapies, including idelalisib

Table 6).

(with or without rituximab) and venetoclax. Patients given ibrutinib

The overall rate of ibrutinib discontinuation was 36%. The main

in the fourth line or beyond were subsequently treated with

reason for discontinuation was progressive disease (PD) for R/R

cyclophosphamide-prednisone

chemotherapy;

novel

therapies,

patients, and was AEs for TN patients (Supporting Information

such as BTK inhibitors; or investigational agents under clinical

Figure 1). Discontinuation due to Richter's transformation was higher

development. For R/R patients, data on best responses to the first

in R/R compared to TN patients. Discontinuation due to AEs was

subsequent therapy after ibrutinib were available for 26 patients:

similar for TN and R/R patients and decreased for all patients as

three CRs, three PRs, and eight SDs were observed, with the other

treatment duration increased (Supporting Information Table 6). The

12 patients having PD. The patients achieving CR received an

most common AEs leading to discontinuation (listed as TN or R/R)

investigational agent, EPOCH-R, or doxorubicin, vinblastine, dacar-

were infections (4%/5%); malignant, benign, or unspecified neo-

bazine ± bleomycin (AVD ± B); patients with a PR received ofatu-

plasms (2%/5%); nervous system disorders (3%/1%); cardiac

mumab, cyclophosphamide, doxorubicin, and vincristine (R-CHO),
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A

Onset of Most Common AEs (>20%)a Over Time
Relapsed Refractory

Treatment Naive
Diarrhea

Diarrhea
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>3 years
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URTI

Vomiting

Vomiting

Neutropenia

Neutropenia

Pneumonia

Pneumonia

Muscle spasms

Muscle spasms

Bruising

Bruising

Sinusitis

Sinusitis
0%
a

20%

40%

60%

80%

100%

0%

20%

40%

60%

80%

100%

Occurring in >20% of patients in either the treatment-naive or relapsed/refractory groups.

B

Onset of Grade ≥3 AEs (>3%)a Over Time
Treatment Naive

Relapsed Refractory

Neutropenia

Neutropenia

Pneumonia

Pneumonia

Anemia

Anemia

0–1 year
1–2 years

Hypertension

0–1 year
1–2 years

Hypertension

2–3 years
Hyponatremia

2–3 years
Hyponatremia

>3 years

Atrial fibrillation

Atrial fibrillation

Diarrhea

Diarrhea

Thrombocytopenia

Thrombocytopenia

Febrile neutropenia

Febrile neutropenia

Urinary tract infection

Urinary tract infection

Back pain

Back pain

Fatigue

Fatigue

Leukocytosis

Leukocytosis
0%
a

20%

40%

60%

80%

100%

>3 years

0%

20%

40%

60%

80%

100%

Occurring in >3% of patients in either the treatment-naive or relapsed/refractory groups.

F I G U R E 3 Time-based analysis of adverse events with ibrutinib treatment. A, Onset of most common AEs (of any grade occurring in ≥20% of
patients) by treatment year. B, Onset of most common grade ≥3 AEs (occurring in ≥3% of patients) by treatment year. AEs, adverse events; URTI,
upper respiratory tract infection
or venetoclax. The eight patients who had SD received either an

4 | DISCUSSION

anti-CD20 monoclonal antibody-based therapy (n = 4), EPOCH
(n = 1), or an anti-CD52 monoclonal antibody-based regimen (n = 3).

This integrated analysis of two phase 3 studies supports the utilization

The 12 patients who progressed had subsequent therapies that

of ibrutinib as the choice for first-line therapy and also demonstrates

included anti-CD20 monoclonal antibodies, anti-CD52 monoclonal anti-

that treatment with ibrutinib does not impair the ability to utilize

bodies, PI3K inhibitors, or chemotherapy-based regimens.

other active therapies including chemoimmunotherapy or venetoclax,
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TABLE 1

Summary of outcomes following ibrutinib discontinuation
Subgroups by prior lines of therapy
0 (n = 30)

1/2 (n = 22)

≥3 (n = 30)

10

15

18

Median OS, months (95% CI)

NR (5.9-NE)

9.3 (7.8-22)

8.9 (4.3-NE)

Median OS post-DC due to PD, months

22.7 (0.6-22.7) [n = 5]

8.7 (0.5-16) [n = 8]

8.9 (2.8-NE) [n = 19]

Median OS post-DC due to AE, months

NR (5.9-NE) [n = 22]

15.5 (6.9-22) [n = 9]

NR (2.6-NE) [n = 7]

Median follow-up, months
a

Abbreviations: AE, adverse event; DC, discontinuation; NE, not estimable; NR, not reached; OS, overall survival; PD, progressive disease.
Six patients who discontinued study ibrutinib to receive commercial ibrutinib are not included.

a

as subsequent lines of therapy. With a median follow-up of 36 and

(17p) were excluded from our study to more accurately compare the

44 months for TN and R/R subgroups, respectively, median PFS was

study population in the RESONATE-2 study. Thus, this analysis can-

not reached for patients with 0 and 1-2 prior lines of therapy and was

not evaluate the impact of these higher risk markers.

41 months for those with ≥3 prior lines. Median OS was not reached

Among previously treated patients, those receiving ibrutinib in

regardless of number of prior lines of therapy. The ORR was high

earlier (1-2 prior) lines of therapy experienced better survival out-

(88%-96%) for all subgroups with highest CR rates for TN patients,

comes compared with those receiving ibrutinib in later (≥3 prior) lines

and the proportion of CRs increasing over time. Independent of the

of therapy. There was a significant difference in PFS between patients

number of prior treatments, ibrutinib resulted in sustained improve-

who received 0 versus ≥3 lines of therapy and 1-2 versus ≥3 lines of

ments in hematologic parameters in most patients with baseline ane-

therapy; the difference in PFS between patients receiving 0 versus

mia or thrombocytopenia.

1-2 lines of therapy was not significant. These findings are consistent

AEs with ibrutinib were largely grade 1 to 2, and the safety profile

with the results of an integrated analysis of three randomized studies,

was similar for the TN and R/R subgroups; however, the frequency

which included 620 ibrutinib-treated patients of whom 136 were

of AEs differed. For example, grade ≥3 infections and cytopenias

TN and 66 had received one prior therapy.14 Multivariate analyses

occurred less frequently among TN patients compared with R/R

showed that patients with one prior therapy had better PFS than

patients. These results are consistent with long-term follow-up ana-

patients treated with ibrutinib in later lines. Patients with 0 prior ther-

lyses of phase 2 studies of ibrutinib in CLL,11,12 and are further sup-

apies demonstrated longer survival compared with patients with ≥3

ported by the infrequent use of growth factors, IVIG, and transfusions

prior lines of therapy. This observation is true of most therapies for

among TN patients in this analysis. We also observed that the fre-

CLL, and the effect of more prior therapies may be less with ibrutinib

quency of most AEs decreased over time. Grade ≥ 3 hypertension

than with other therapies. There was no significant difference in OS

occurred more frequently after the first year of ibrutinib among previ-

between patients who received 0 versus 1-2 or 1-2 versus 3 lines of

ously treated patients. Although an increase in the prevalence of

therapy. This suggests that patients who have PD on first-line therapy

hypertension would be expected over time in any aging population,

may be able to receive ibrutinib therapy as second-line therapy with-

the frequency of hypertension was found to be higher with ibrutinib

out any adverse consequences.

6

than in the comparator arm in RESONATE-2. Patients in this analysis

Moreover, survival following ibrutinib discontinuation was compa-

received ibrutinib for longer durations on average than patients

rable with survival following discontinuation of other single-agent

receiving comparator drugs; this may partially explain the higher prev-

therapies, as shown in our analysis of OS outcomes in the comparator

alence of hypertension in the ibrutinib arm.

arms. Although patient numbers are small, those treated after ≥3 prior

Discontinuation of ibrutinib due to AEs occurred at a similar rate

lines of therapy who discontinued ofatumumab and did not cross over

in the TN patients and R/R subgroups without a specific AE markedly

to ibrutinib appeared to have the poorest outcomes with median OS

predominant; however, the rate of discontinuations due to AEs among

of <3 months.

13

Discontin-

Analyses of ibrutinib-treated CLL patients reported poor survival

uation due to PD occurred in 12% of patients, similar to the rate of

following discontinuation of ibrutinib.9,10 One single-institution study

progression-related ibrutinib discontinuation previously reported

reported poor salvageability of 33 patients treated with regimens

real-world patients in a retrospective analysis was higher.

9,10

Patients treated with ibrutinib in earlier lines also

including chemoimmunotherapy or ofatumumab following ibrutinib

tended to have lower rates of progression and experienced better

discontinuation.9 Another study of pooled data from 308 patients

PFS and OS outcomes relative to more heavily treated patients. The

treated with ibrutinib in four clinical studies confirmed the poor prog-

risk of progression on ibrutinib has previously been reported to

nosis of patients after discontinuation of ibrutinib.10 These analyses

(10%-12%).

increase with high-risk factors like del(17p), unmutated IGHV, complex

also revealed that patients who discontinued because of PD with

karyotype, or BCL6 abnormalities.9,10 In our analysis, TN patients

transformation (Richter's or other) had dismal outcomes with median

tended to have a lower frequency of unmutated IGHV and complex

OS of 2.6 to 3.5 months post-ibrutinib discontinuation.9,10 In con-

karyotype than patients with R/R disease; data from patients with del

trast, median OS ranged from 17.6 months to not reached among
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patients who discontinued because of PD without transformation.10
Initial reports from these studies indicated that patients who discontinued because of nonrelapse reasons (including AEs) also had a poor
prognosis following ibrutinib discontinuation.9,10 However, these
reports primarily included very high-risk patients with combinations
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